The oral or Forglipron weight loss drug could replace Ozempic, Wegovy if approved

A oral weight loss pill has worked well in clinical trials, positioning it as a potential alternative to injectable GLP-1 drugs such as Ozempic and Wegovy.

The drug Eli Lilly, called Orforglipron, has demonstrated “significant weight loss” and cardiometabolic improvements, according to a press release.

Phase 3 Attan-1 test, which was published in the New England Journal of Medicine, has evaluated the safety and effectiveness of the drug in adults who have a weight-related medical problem and have no diabetes.

Weight loss drugs could add years to the life of Americans, the researchers’ project

The participants underwent 72 weeks of treatment with three different doses (6 mg, 12 mg and 36 mg).

After the trial period, the results showed that OrForglipron encountered the “primary assessment criterion for the higher reduction in body weight” compared to a placebo.

The new GLP-1 pill could replace injectable drugs for weight loss, suggests the study. (istock)

Those who took the highest dose lost an average of 27.3 pounds. Almost 60% of these participants lost 10% of their body weight, while 39.6% lost at least 15%.

Of the 1,127 participants who had a pre-diabetes at the start of the study, up to 91% reached almost normal blood sugar compared to the 42% taking a placebo, the researchers revealed.

Orforglipron has shown “clinically significant improvements” of cardiovascular risk factors associated with obesity, such as non -HDL cholesterol, systolic blood pressure and triglycerides.

Popular weight loss drugs could relieve the painful symptoms of arthritis, report doctors

The highest dose has also reduced a marker for inflammation, called high sensitivity C-reactive protein by 47.7%.

The study revealed that the safety profile of the drug was in accordance with existing GLP-1 drugs. The most common side effects were gastrointestinal, including nausea, constipation, diarrhea and vomiting, with mild to moderate severity.

Participants who took the highest dose lost an average of 27.7 pounds after more than a year of use. (istock)

Sean Wharton, MD, director of the Wharton Medical Clinic and the main study author in Canada, wrote in a press release that obesity is a “comprehensive overall health challenge” requiring effective and easy -to -integrate treatment options in daily life “.

“ Next Ozempic ‘aims to provide weight loss of 30% with fewer side effects

“In this phase 3 study, Orforglipron has shown strong efficiency results and security in accordance with the GLP-1 class, strengthening its potential as a first-line treatment in primary care,” he said in the press release.

“Orforglipron could help reduce known markers of cardiovascular risk associated with obesity and support significant improvements in public health.”

Eli Lilly and the company’s registered office are based in Indianapolis, Indiana. (istock)

Lilly announced that she was going ahead with plans to obtain the approval of Orforglipron as an obesity medication. The company expects that it can obtain the green light from 2026. The same year, it also plans to request approval to use the drug for the treatment of type 2 diabetes.

Reuters reported that this pill could be “accelerated” as part of a one to two -month examination process launched by the Food and Drug Administration, according to Wall Street analysts.

Click here to obtain the Fox News app

“Analysts speculate that the drug, Orforglipron, is a viable candidate given the burden on the growing costs of costly injectable weight loss drugs and the fact that Lilly extends its American manufacturing – issues the administration that the Trump administration has hierarchical,” wrote Reuters.

Click here to register for our Health Newsletter

In an interview with Fox News Digital, Sue Decotiis, MD, doctor of medical weight loss in New York, described this medication “positive addition to the armament” which is cheaper to produce and cheaper for the consumer.

Decotiis, however, noted that the results of the weight loss are “not as impressive” as the results of injectables like Ozempic and Mounjaro.

A weight loss doctor says that the injectable results of GLP-1 are more impressive than the pill. (istock)

“However, compliance with Orforglipron can be better, because it is an oral drug and not an injectable,” she said.

According to Decotiis, a concern for this new drug is that it is not a peptide, which has a high safety factor and is “easy for the body to metabolize and adapt”.

For more health items, visit www.foxnews.com/health

“There could be unknown long-term consequences that we have not yet known,” she added. “I think there will be more weight loss drugs in the pipeline and I hope they will be in the peptides category.”

Fox News Digital contacted Eli Lilly to comment.